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Abstract: Streptomyces remains one of the prolific sources of structural diversity, and a reservoir to 
mine for novel natural products. Continued screening for new Streptomyces strains in our 
laboratory led to the isolation of Streptomyces sp. RK44 from the underexplored areas of Kintampo 
waterfalls, Ghana, Africa. Preliminary screening of the metabolites from this strain resulted in the 
characterization of a new 2-alkyl-4-hydroxymethylfuran carboxamide (AHFA) 1 together with five 
known compounds, cyclo-(L-Pro-Gly) 2, cyclo-(L-Pro-L-Phe) 3, cyclo-(L-Pro-L-Val) 4, cyclo-(L-Leu-
Hyp) 5, and deferoxamine E 6. AHFA 1, a methylenomycin (MMF) homolog, exhibited anti-
proliferative activity (EC50 = 89.6 µM) against melanoma A2058 cell lines. This activity, albeit weak 
is the first report amongst MMFs. Furthermore, the putative biosynthetic gene cluster (ahfa) was 
identified for the biosynthesis of AHFA 1. DFO-E 6 displayed potent anti-plasmodial activity (IC50 
= 1.08µM) against P. falciparum 3D7. High-resolution electrospray ionization mass spectrometry (HR 
ESIMS) and molecular network assisted the targeted-isolation process, and tentatively identified six 
AHFA analogues, 7–12 and six siderophores 13–18. 




Streptomyces have been, for decades, one of the most prolific sources of pharmacologically-active 
compounds, contributing for more than half of the naturally-derived antibiotics that are in clinical 
use today, such as chloramphenicol (from S. venezuelae) [1], fosfomycin (from S. fradiae) [2], clavulanic 
acid (from S. clavuligerus)[3], and avermectin (from S. avermitilis)[4]. In our efforts to discover natural 
products, we have isolated a new bacterial strain, Streptomyces sp. RK44 from the underexplored areas 
of Kintampo waterfalls, Ghana, Africa [5,6]. 
Chemical profiling of the RK44 extract using high-resolution electrospray ionization mass 
spectrometry (HR-ESIMS) and Global Natural Product Social (GNPS) molecular network (MN) [7] 
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showed a cluster of low molecular weight metabolites with a characteristic 250 nm UV absorption, 
suggesting that they share a common chromophore skeleton. Database dereplication using AntiBase 
2017 (WILEY) and other online databases (The Natural Products Atlas, ChemSpider) [8,9] revealed 
that these metabolites have not been previously described in the literature [10,11]. 
The isolation was carried out and afforded a new metabolite 1 (1.0 mg). Interpretation of the 
spectroscopic data demonstrated that 1 is 2-alkyl-4-hydroxymethylfuran-3-carboxamide (AHFA), a 
new methylenomycin furan (MMF) homolog which bears an amide moiety at C-3 instead of 
carboxylic acid [12] in the former. MMFs are signalling molecules or autoregulators identified in 2008 
in the model actinomycete Streptomyces coelicolor, which induce methylenomycin antibiotic 
production [10]. Examples of the well-characterized autoregulators include acylhomoserine lactones 
(AHLs) in Gram-negative bacteria [13] and γ-butyrolactones (GBLs) in Gram-positive bacteria of the 
genus Streptomyces [14,15]. 
Genome mining revealed that the furan-type autoregulators may be widespread in Streptomyces 
species [10], however, only one class of MMFs has been identified to date [12]. The discovery of this 
new class of 2-alkyl-4-hydroxymethylfuran-3-carboxamide signalling molecule, AHFA 1 further 
expanded the chemical space of the under-explored class of furan-based autoregulators, and the 
MMF biosynthetic machinery. Furthermore, the presence of AHFA 7–10, bearing various alkyl 
substituents at C-2 of the furan ring was also detected by high-pressure liquid chromatography 
(HPLC)-Ultraviolet (UV)-HRESIMS-GNPS analyses, but they were not isolated due to their trace 
quantities in the extract. 
Along with AHFA 1, we also isolated known compounds, cyclo-(L-Pro-Gly) 2, cyclo-(L-Pro-L-
Phe) 3, cyclo-(L-Pro-L-Val) 4, cyclo-(L-Leu-Hyp) 5, and deferoxamine E 6. Moreover, the MN analysis 
also identified the clusters corresponding to diketopiperazines 2–5, and siderophores 6 and 13–18. 
2. Results and Discussion 
A large-scale fermentation (6L) of Streptomyces sp. RK44 in Modified Bennett’s broth [16] was 
performed for seven days (28 °C, 180 rpm). Subsequently, Diaion® HP-20 (3 g/50 mL) was added to 
the culture broth and incubated overnight under the same culture conditions. The mixture was 
filtered under vacuum, after which the residue consisting of the mycelium and HP-20 resin was 
submerged in 100% methanol (3 × 500mL) for 24 h. The methanol extract was then decanted and 
concentrated under reduced pressure to give a crude extract (5.8 g) which was then fractionated by 
solid-phase extraction (SPE) using Strata® C18-E to give six fractions (S1–S6). 
Dereplication of SPE extracts of RK44 using GNPS and a survey of databases (e.g., Dictionary of 
Natural Products, AntiBase, The Natural Products Atlas) suggested the presence of potentially new 
metabolites cluster in fraction S3. Consequently, S3 was selected for further purification using semi-
preparative reversed-phase HPLC to yield 1 (1.0 mg), along with a number of diketopiperazines 2 
(1.2 mg), 3 (2.0 mg), 4 (2.1 mg), 5 (2.3 mg), and the known siderophore, deferoxamine E 6 (3.0 mg) 
(Figure 1). 
2.1. Structure Elucidation 
The structures of the diketopiperazines (DKPs), cyclo-(L-Pro-Gly) 2, cyclo-(L-Pro-L-Phe) 3, 
cyclo-(L-Pro-L-Val) 4, and cyclo-(L-Leu-Hyp) 5, were determined by comparison of the UV spectra, 
molecular formulae, and a series of Nuclear magnetic resonance (NMR) spectra with literature data 
[17–21] (Figure S21–S24, Table S2). The configuration of 2–5 were determined by advanced Marfey’s 
analysis, suggesting that all the proteogenic amino acids are in L-configuration (Table S4). Compound 
6 was identical to the reported siderophore, desferrioxamine E 6 [22–24] (Figure S22, Table S3). 
Compound 1 was obtained as a yellow powder. The molecular formula of 1 (Figure 1) was 
established as C10H15NO3 by High-Resolution Electrospray Ionization Mass Spectrometry (HR-
ESIMS) (calculated [M+H]+ = 198.1123; observed [M+H]+ = 198.1125; ∆ = −0.5047 ppm), indicating 4 
degrees of unsaturation (Figure S1). The UV absorption maximum at 250 nm found in its spectrum is 
a characteristic feature of MMF molecules. 
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Analysis of the 1H, HMBC, and HSQC spectra revealed the presence of 1 sp2 methine, 4 
methylenes, 1 methyl, and 4 quaternary carbons leading to the sub-formula C10H12. The 1H-NMR 
spectrum in CD3OD contained signals for 12 of the 15 protons accounted by the molecular formula, 
suggesting three exchangeable protons. These protons were observed in the DMSO-d6 spectrum at δH 
6.53 (NH2) and δH 4.05 (OH). The remaining oxygen atom and the 13C chemical shifts (δC 162.1, 123.1, 
139.1, 115.8), and the number of double bond equivalents suggested the presence of a furan core in 
the structure, which is supported by the heteronuclear multiple bond correlations (HMBC) from H-5 










Figure 1. Isolated metabolites from Streptomyces sp. RK44. structures of which were elucidated by 
NMR. Structure of AHFA 1 with COSY (―) and key HMBC (→) correlations. 
Inspection of the 1H-1H COSY data identified one spin system from H-1′to H-4′, indicative of a 
butyl alkyl chain. The cross peak from H2-1′ (δH 2.95, t) to C-2 (δC 162.1) established the connectivity 
of the butyl alkyl group to the furan framework. The observed downfield signal at δH 4.52 (H2-7, s) 
suggested a hydroxymethylene group, and it was placed at C-4 based on the strong HMBC from H-
7 (δH 4.52) to C-3 (δC 115.8), C-4 (δC 123.1), and C-5 (δC 139.1). The carbonyl carbon at C-6 (δC 171.6) 
and the N-H signal (δH 6.53, 2H) obtained in DMSO-d6 accounted for an amide moiety, and its 
connectivity was assigned to the remaining quaternary carbon C-3 (δC 115.8) of the furan ring.  
Final structural analysis of 1 was confirmed by comparison with the spectroscopic data reported 
for MMF4 [12], which differs with 1 in the presence of a carboxylic acid in the former instead of the 
amide at position C-3. Compound 1 was therefore identified as 2-alkyl-4-hydroxymethylfruan 
carboxamide (AHFA). 
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Table 1. NMR data of AHFA 1 in CD3OD and DMSO-d6 at 600 MHz and 298 K  
  CD3OD  DMSO-d6 
POSITION 13C (ppm) 1H (Integral, Mult.) 13C (ppm) 1H (Integral, Mult.) 
4′ 12.7 0.92 (3H, t) 13.9 1.01(3H,t) 
3′ 21.9 1.35 (2H, hep) 21.9 1.41(2H, hep) 
2′ 29.8 1.63 (2H, pent) 29.9 1.68(2H, pent) 
1′ 26.6 2.95 (2H, t) 26.4 3.03(2H, t) 
2 162.1 - 161.3  - 
7 54.1 4.52 (2H, s) 54.1 4.53(2H, s) 
6 171.6 - 169.9  - 
5 139.1 7.38 (1H, s) 138.9 7.64(1H, s) 
4 123.1 - 124.2 - 
3 115.8 - 117.0 - 
NH2 - - - 6.53(2H, br) 
OH - - - 4.05(1H, br) 
MMFs share the common furan core in the structure, and the alkyl substituents at position C-2 
of the ring can vary depending on which starter unit is incorporated during fatty acid biosynthesis 
[12,25]. Based on the HR ESIMS/GNPS analysis of the Streptomyces sp. RK44 extract, we have 
tentatively identified six AHFA 1 analogues, 7–12, with various lengths in their carbon alkyl chains 
at C-2 of the furan ring (Figures S10–S16, Table S1). However, they could not be isolated due to their 
presence in the extract in minute amounts. AHFA 7–12 clustered together in the molecular network 
(MN) signifying that they share a common structural motif evident in the presence of the furan 
framework (Figure S10). Detailed analysis of the UV pattern, MS and MS2 fragmentation data showed 
that they exhibit the characteristic UV absorption at 250 nm of MMFs, and the alkyl chain substitution 
at position C2 of the ring, analogous to the MMFs that have been reported previously [12]. 
Further MN analysis also identified the clusters corresponding to the DKPs 2–5, deferoxamines 
(DFO) B and E 6 and the 2.5kDa RIPP peptide (Figure S9). The observed molecular ion peaks of 13–
18 matched with the known ions in the GNPS library and they clustered together in the network, 
suggesting that they could be potentially new siderophores. Moreover, their fragmentation pathway 
were proposed based on the observed MS/MS data (Figure S20). Characterization of the peptide is 
currently underway in our laboratory. 
2.2. Proposed MMF Biosynthetic Gene Cluster and Pathway 
The biological function of AHFA 1 in the host cell is still unknown but is believed to be regulators 
of antibiotic biosynthesis in Streptomyces sp. RK44, analogous to the MMFs in S. coelicolor and GBLs 
in Streptomyces species [12,25]. Given the structural similarity of 1 with MMF4 [12], we predicted that 
1 originated from an analogous biosynthetic pathway of MMF4. In silico analysis of the annotated 
RK44 genome using antiSMASH 3.0 [26] revealed one putative biosynthetic gene cluster, BGC (ahfa) 
that is likely to be involved in the biosynthesis of AHFA 1. Pairwise comparison of the annotated 
proteins using BLAST [27] and the sequence similarity network (SSN) [28] between the ahfa cluster 
with the mmf BGC showed high amino acid identity, supporting its role in MMF homolog 
biosynthesis (Figure 2). 
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Figure 2. Comparison of the ahfa BGC in Streptomyces sp. RK44 with the mmf gene cluster on the SCP1 
plasmid of S. coelicolor A3(2). Homologous genes are colored the same, and sequence identities 
between each of the encoded proteins are indicated in Table 2. 
The ahfa gene cluster spans about 4.5 kb of genomic DNA and contains three biosynthetic genes 
(ahfaL, ahfaP, ahfaH) that are likely involved in the biosynthesis of AHFA 1 in Streptomyces sp. RK44 
(Table 2, Scheme 1). The incorporation of stereospecifically 13C-labeled glycerols into the MMFs 
suggested that they are biosynthesized via a butenolide phosphate intermediate 22 [25], derived from 
the MmfL-catalysed condensation of coenzyme A β-ketothioesters 19 in fatty acid biosynthesis with 
dihydroxyacetone (DHAP) 20. The isotope-labelled studies indicated that the hydroxymethyl group 
in MMFs originated from the hydroxymethyl of DHAP, suggesting an analogous role of AhfaL to the 
AfsA in the biosynthesis of A-factor [29], in contrary to the alternative roles proposed by Sello and 
colleagues (2009) [30]. AhfaL which encodes for butenolide synthase in RK44 with 53% identity to 
mmfL and 42.0% similarity to afsa is proposed to catalyse a similar condensation reaction between 3-
oxohexanoyl-thioester 19 and DHAP 20 to yield 21, then 22. AhfaP encoded for phosphatase and has 
58% identity to MmfP is likely responsible for the dephosphorylation of butenolide 22 to form 23, 
followed by rearrangement to 24 catalysed by the flavin-dependent monooxygenase, AhfaH. The 









Scheme 1. Proposed biosynthesis pathway of 1. 
Furthermore, two putative genes, ahfaR and ahfaS which encode for TetR/AcR transcriptional 
repressor showed high amino acid identities to MmfR and MmyR (46/62, WP_011039544.1; 62/75, 
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WP_011039548.1) in S. coelicolor [31], respectively, were likely responsible for the antibiotic regulation 
in RK44. 
The deduced function of ahfaL,H,P genes, based on their homology to autoregulatory genes 
(mmf or afs) of known function, supports the structure and the probable role of AHFA 1 as a signalling 
molecule. 
Table 2. Deduced functions of open reading frames (ORFs) in ahfa biosynthetic gene cluster. 
Protein AA 
Homologue 
(% Identity / % Similarity) 
Predicted Encoded Function 
AhfaR 210 
MmyR (62/75) S. coelicolor A3(2)  
A factor receptor (30/48) S. griseus  
TetR/AcR family transcriptional regulator 
AhfaP 243 MmfP (46/58) S. coelicolor A3(2) Phosphatase / Hydrolase 
AhfaH 384 MmfH (58/66) S. coelicolor A3(2) Oxidoreductase 
AhfaL 334 
MmfL (42/53) S. coelicolor A3(2) 
AfsA (32/42) S. griseus  
Butenolide synthase /  
A factor biosynthesis 
AhfaS 216 MmfR (46/62) S. coelicolor A3(2) TetR/AcR family transcriptional regulator 
2.3. Biological Test 
AHFA 1 inhibited proliferation and viability of human A2058 melanoma cells and induced 
anoikis (EC50 = 89.6µM) (Figure 3B) compared to control (treated with culture media alone, Figure 
3C). It is worth noting that, although weak, this activity is the first time to be reported amongst MMFs 
(Figure S23). Compounds 2–6 did not display any bioactivity at the highest concentration tested (50 
µM). 
 
Figure 3. (A) A2058 cell treated with 50µg/mL staurosporine (B) A2058 cell treated with 50µg/mL 
AHFA 1 (C) A2058 cell treated with culture media. Cell viability was quantified by Aqueous One 
Solution Reagent by a colourimetric method for determining the number of viable cells in 
proliferation or cytotoxicity assays. A2058 cells were left untreated or were treated with AHFA 1 for 
72 h and morphological changes of the cells were observed by light microscope (Scale bar 26 μm). 
Compounds 1–6 were also investigated for their anti-plasmodial activities against Plasmodium 
falciparum 3D7. Only 6 showed potent antimalarial activity (IC50 = 1.08µM), and 1–5 did not display 
any bioactivity at the highest concentration tested (50 µM). The activity of 6 may result from the 
strong chelation of DFO-E 6 with iron from the culture medium of P. falciparum, causing iron deficit 
and finally cell death [32]. This observation was consistent with the reported antiplasmodial activities 
of siderophores in literature [33–36]. 
On the other hand, there are no significant antimicrobial activities observed in 1–6 against the 
Gram-negative pathogens, Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 at 
concentrations between 0–50 µg/mL. 
  
Healthy Cells Dead Cells 
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3. Materials and Methods  
3.1. Fermentation 
Streptomyces sp. RK44 was isolated from the soil near Kintampo waterfall, Ghana, Africa. The 
soil isolate was streaked on an ISP2 agar plate (yeast extract 4 g, malt extract 10 g, glucose 4 g, 15 g 
agar, in 1L H2O) to get pure single colonies. One single colony was inoculated into 50 mL of Modified 
Bennett’s liquid medium (glycerol 10.0 g, Oxoid yeast extract 1.0 g, Bacto-Casitone 2.0, Lab-Lemco 
0.8 g in 1000 mL MilliQ H2O), and incubated for three days at 28 °C with shaking at 180 rpm (Incu-
shake FL16-2). This seed culture was used to inoculate 6.0 L of MB broth (1:100) in 12 baffled flasks 
(CorningTM polycarbonate flasks), each containing autoclaved MB medium (500 mL) and plugged 
with Fisherbrand™ polyurethane foam stoppers (Fisher Scientific, UK). The cultures were fermented 
for seven days under the same condition as the seed culture. On day 7, Diaion® HP-20 (3 g/50 mL) 
was added to the fermentation culture under sterile conditions. The flasks were left in the same 
shaking temperature and conditions for 16–22 h. The culture broth was filtered under vacuum (Buchi 
pump V100, UK), and the HP-20 resin was washed with MilliQ water and extracted thrice with 100% 
methanol (Fisher Chemical HPLC grade). All the methanol extracts were combined, concentrated 
under reduced pressure (Buchi Rotavapor R200, BUCHI, UK), and subjected to High-resolution 
Electrospray Ionization Liquid Chromatography Mass Spectrometry (HRESI-LC-MS, Thermo 
Scientific, UK) analysis. 
3.2. Molecular Network Analysis 
MSConvert software (3.0, Proteowizard, CA, US) was used to convert LCMS.RAW data to the 
mzXML format files. MZmine was used to preprocess the data and exported to the GNPS platform 
for molecular networking data analysis [37]. The GNPS analysis was achieved through the GNPS 
data analysis workflow using the spectral clustering algorithm [38]. Data analysis was performed 
using the following settings: parent mass tolerance 0.02 Da, ion tolerance 0.02 Da, minimum pairs 
cosine 0.7, minimum matched peaks 6, network TopK 10, minimum cluster size 2, and maximum 
connected component size 100. The spectral library matching was performed with a similar cosine 
threshold and minimum matched peaks. The spectral networks were imported into Cytoscape 3.6.1 
and visualized using the force-directed layout [39]. 
3.3. Spectroscopic Analysis  
HR-ESI-LC-MS was obtained using an LTQ Orbitrap LC-MS system (Thermo Scientific, UK) 
coupled to a Thermo Instrument HPLC system (Accela PDA detector, Accela PDA autosampler and 
Accela Pump) on a positive ESI mode (30,000), MS/MS resolution 7500, C18 (Sunfire 150 × 46 mm 
column). 0.1% formic acid in water and 0.1% formic acid in acetonitrile was used for reverse-phase 
separation using a gradient from 0–100% in 25 min. The instrument parameters were set as following: 
Capillary voltage 45 V, spray voltage 4.5 kV, capillary temperature 200 °C, auxiliary gas flow rate 10–
20 arbitrary units, sheath gas flow rate 5 arbitrary units, mass range 150–2000 amu (maximum 
resolution 30,000×), MS scan 150–2000Da coupled with an automated full dependent MS-MS scan. 
1D and 2D NMR data were obtained on a Bruker AVANCE III HD 600 MHz (AscendTM14.1 
Tesla, UK) with Prodigy TCITM cryoprobe at 298 K in DMSO-d6 and CD3OD (Goss Scientific). 
Trimethylsilane (TMS) was used as an internal standard.  
3.4. Fractionation of the Extract 
Fractionation of the crude methanol extract was achieved by using Strata® C18-E solid-phase 
extraction (SPE) (55 µm, 70 Å, 20 g/60 mL) cartridges. The SPE column was initially washed with two 
column volumes (CV) of methanol and MilliQ water separately, and then, the crude sample was 
loaded onto the column. The column was then eluted stepwise with solvent mixtures of decreasing 
polarity (8CV/solvent mixture): Milli-Q H2O, 25% MeOH, 50% MeOH, 75% MeOH, 100% MeOH, and 
100% MeOH with 0.05% trifluoroacetic acid (Acros Organics). The eluents were collected separately 
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and labelled as fractions S1–S6. All the fractions were concentrated under reduced pressure (Buchi 
Rotavapor R200) and subjected to HR-ESI-MS analysis. 
Mass spectrometry (MS) analysis was carried out in all the fractions (S1–S6) to target the MMF 
signalling molecules. Analysis of the HRESI-LC-MS data of fraction S3 revealed seven resolved peaks 
with [M + H]+ ions at m/z 184.0967, 198.1123, 212.128, respectively. Dereplication of these masses was 
achieved using AntiBase (2017), indicating that these molecules were previously unreported but 
might share a similar furan core as MMF molecules. Thus, fraction S3 was selected for further 
fractionation by reversed-phase semi-prep (C18 ACE 10 µM 10 × 250 mm column) HPLC (Agilent 
1260 Infinity). The purification was carried out using a linear gradient from 20% H2O: MeOH (95:5) 
to 100% MeOH for 28 min with a solvent flow rate of 1.5 mL/min, to yield AHFA 1 (1.0 mg). Six other 
furan derivatives, 7–12 were identified in the same fraction by HRESI-LC-MS and molecular network 
analyses (Figure S9, Table S1). However, these molecules could not be isolated due to their presence 
in trace quantities in the extract. Compound 2–6 were isolated in the fraction S2, using a linear 
gradient from 10% H2O: MeOH (95:5) to 100% MeOH for 28 min with a solvent flow rate of 1.5 
mL/min. 
Along with 1, we also isolated cyclo-(L-Pro-Gly) 2, cyclo-(L-Pro-L-Phe) 3, cyclo-(L-Pro-L-Val) 4, 
cyclo-(L-Leu-Hyp) 5, and deferoxamine E 6.  
AHFA 1: 1.0mg; pale yellow powder. UV (CH3OH): 250 nm; 1H, 13C-NMR data, see Table 1; 
HRESIMS (positive mode) m/z calculated [M + H]+ = 198.1125; observed [M + H]+ = 198.1123; ∆ = 
−0.5050 ppm. 
cyclo-(L-Pro-Gly) 2: 1.2 mg; white solid; 1H, 13C-NMR data, see Figure S21, Table S2; HRESIMS 
(positive mode) m/z calculated [M + H]+ = 155.0815; observed [M + H]+ = 155.0821; ∆ = 2.870 ppm. 
cyclo-(L-Pro-L-Phe) 3: 2.0 mg; pale yellow solid; 1H, 13C-NMR data, see Figure S22, Table S2; 
[α]25D= -17.2 (c 1.0, MeOH); HRESIMS (positive mode) m/z calculated [M + H]+ = 245.1285; observed 
[M + H]+ = 245.1276; ∆ = −2.631 ppm. 
cyclo-(L-Pro-L-Val) 4: 2.1 mg; pale yellow solid; 1H, 13C-NMR data, see Figure S23, Table S2; [α]25 
D = - 31.0 (c 1.0, MeOH); HRESIMS (positive mode) m/z calculated [M + H]+ = 197.1285; observed [M + 
H]+ = 197.1284; ∆ = −0.5070 ppm. 
cyclo-(L-Leu-Hyp) 5: 2.3 mg; yellow solid; 1H, 13C-NMR data, see Figure S24, Table S2; [α] 25D = -
11.6 (c 1.0, MeOH); HRESIMS (positive mode) m/z calculated [M + H]+ = 227.1390; observed [M + H]+ 
= 227.1392; ∆ = −0.7040 ppm. 
Deferoxamine E 6: 3.0 mg; pale yellow solid; 1H, 13C-NMR data, see Figure S25, Table S3; 
HRESIMS (positive mode) m/z calculated [M + H]+ = 601.3356; observed [M + H]+ = 601.3350; ∆ = −1.031 
ppm. 
3.5. Advanced Marfey’s Experiment 
Compounds 2–5 (0.5mg) were hydrolysed in 6 N HCl (1 mL) for 17 h at 115 °C. The hydrolysate 
was evaporated to dryness, dissolved in H2O (100 µL), and then, treated with 1 M NaHCO3 (20 µL), 
and FDLA, fluorodinitrophenyl-5-L-leucine amide (1% solution in acetone, 100 µL). The mixture was 
incubated at 40 °C for 1 h. The reaction was neutralized by addition of 2 N HCl (20 µL) and 
evaporated to dryness at 40 °C under a stream of dry N2. The residue was dissolved in CH3OH (500 
µL) and filtered (0.45 μm PTFE) prior to HPLC-Diode Array Detection (DAD) analysis. The 
separation was carried out using gradient elution CH3CN/H2O with 0.1% TFA (from 0% to 100% for 
30 min, flow rate 1.0 mL/min, UV detection λmax 340 nm). 
The standard amino acids were derivatized with FDLA and analyzed by HPLC-DAD in the same 
manner as the test compounds. 
3.6. Genome Sequencing of Streptomyces sp. RK44 
The genome sequencing of Streptomyces sp. RK44 and the sequencing assembly service were 
provided by BGI-Shenzhen, China. A 300 bp paired-end genomic library of RK44 was prepared for 
Illumina sequencing. A total of 11,820,095 bp were obtained and assembled by SOAP denovo 
software. The assembled genome was submitted to the RAST server for annotation [40]. The open 
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reading frames (ORFs) of the ahfa gene cluster was identified using the key enzymes encoded in the 
known mmf gene cluster as a sequence query. The 16s rDNA sequences and the ahfa cluster has been 
deposited in the NCBI (MN906804). 
Based on the partial 16s DNA gene sequence analysis it was identified that the strain belongs to 
the class Streptomyces and was most closely related to three strains with 82.49% sequence similarity: 
Streptomyces hoynatensis S1412, Streptomyces carpaticus NRRL B-16359, Streptomyces yeochonensis NBRC 
100782. The strain formed a well-separated clade in the genus Streptomyces (Figure 4) based on the 
16S rRNA gene analysis, indicating that Streptomyces sp. RK44 is a new Streptomyces species (MEGA 
7, Neighbor-Joining method) [41,42]. The optimum pH for growth was determined to be 7.2. The 
DNA G+C content of the strain was determined to be 71.4 mol%. 
 
Figure 4. Phylogenetic analysis of 16S rDNA sequences of Streptomyces sp. RK44 and other known 
Streptomyces species, indicating that Streptomyces sp. RK44 is a new Streptomyces species. 
3.7. Sequence Similarity Network 
The sequence similarity network (Figure 2) of the biosynthetic gene clusters of Streptomyces sp. 
Rk44 and Streptomyces coelicolor A3(2) was constructed by all-to-all BLASTP comparison of sequences 
found in strains containing essential biosynthetic genes involved in the MMF and AHFA 
biosynthesis. Each node represents a gene and each edge represents the BLASTP pairwise 
comparison (E-value > 1 × 10−10) between two gene sequences. The results generated were visualized 
using Cytoscape 3.6.1. The genes, mmfL, H, P, are coloured with red, green, and blue, respectively. 
Other genes in the clusters were coloured with grey [28]. 
3.8. Anti-Proliferative/Cytotoxicity Test 
The anti-proliferative activity of AHFA 1 was tested on the human melanoma A2058 cancer cell 
line (American Type Culture Collection (ATCC) CRL-11147TM, Manassas, VA, USA). Cell lines were 
seeded in 96-well-microtitre plates (Nunc, Thermo Fisher Scientific, NY, USA) at 2000 cells/well in 
Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Scientific, USA) with fetal bovine serum 
(10%, FBS, Sigma Aldrich, USA) and gentamicin (10 µg/mL, Sigma Aldrich, USA). Cells were grown 
at 37 °C in a humidified atmosphere of 5% CO2 and maintained at low passage. 
Toxicity assay was tested on the lung normal cell (ATCC CCL-171).Cell lines were seeded in 96-
well-microtitre plates (Nunc, Thermo Fisher Scientific, CA, USA) at 4000 cells/well in DMEM with 
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FBS (10%) and gentamicin (10 µg/mL). Cells were grown at 37 °C in a humidified atmosphere of 5% 
CO2 and maintained at low passage. 
Cells were incubated for 24 h before AHFA 1 was added and thereafter incubated for 72h. Cell 
viability was determined by a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3 carboxymethoxyphenyl)-
2-(4-sulfophenyl) -2H-tetrazolium (MTS) assay. At the end of the exposure time, 10 µL Cell Titer 96® 
Aqueous One Solution Reagent (Promega, Madison, WI, USA) was added to each well. Results were 
measured after 1 h at 485 nm. The dose-dependent response of AHFA 1 (100 ng/mL, 1, 2.5, 5, 10, 12.5, 
25, and 50 µg/mL) was tested in triplicates. 
3.9. Antibacterial Assay  
Minimum inhibitory concentrations (MIC) were determined using a conventional broth dilution 
assay in accordance with standards recommended by the National Committee for Clinical Laboratory 
Standards (NCCLS)[43]. Gram-negative bacteria Escherichia coli (ATCC 25922) and Pseudomonas 
aeruginosa (ATCC 27853) were used as test organisms. All bacteria were cultured in Mueller–Hinton 
broth. The assays were performed in 96-well plates (Nunc, Thermo Fisher Scientific, NY, USA), 
wherein a 50 µL suspension (log phase) of actively growing bacteria was incubated overnight at 37 
°C and then treated with 50 µL of the test extract (final concentration of 50 μg/mL, for the three 
biological triplicates). The negative control comprised the growth media and Milli-Q water, while the 
positive control consisted of the bacteria plus Milli-Q water. The absorbance was recorded after 24 h 
(OD600) in a Victor3 multilabel plate reader. The growth medium appeared clear in wells where the 
test compound prevented the growth or killed the bacteria; otherwise, it was cloudy. Activity 
threshold was set below 0.05 (OD600). 
3.10. Plasmodium Falciparum 3D7 Lactate Dehydrogenase Assay 
The antiplasmodial activities of 1–6 were assessed by lactate dehydrogenase assay using 
Plasmodium falciparum 3D7 as the test organism. The assay was performed according to the method 
previously described by Pérez-Moreno et al., 2016 [36], in triplicate using a sixteen points dose-
response curve (1⁄2 serial dilutions) with concentrations ranging from 50 μM to 1.5 nM to determine 
the IC50 of the pure compounds. Chloroquine was used as the standard reference. 
4. Conclusions 
Herein, we report the discovery of AHFA 1 from the novel soil bacterium Streptomyces sp. RK44. 
The structure of 1 was deduced by analysis of the HRESIMS, UV, 1D, and 2D NMR, and identified as 
a new AHFA-type natural product. Seven AHFA analogues, 7–12 and siderophores 13–18 were 
tentatively identified in the extract of RK44 by HRESIMS and GNPS molecular network analyses. A 
putative AHFA biosynthetic pathway was proposed for 1. AHFA 1 displayed antiproliferative 
activity against melanoma A2058 cells (EC50 = 89.6µM). Albeit weak, this represents the first report of 
such activity amongst MMF molecules. Five other known metabolites, cyclo-(L-Pro-Gly) 2, cyclo-(L-
Pro-L-Phe) 3, cyclo-(L-Pro-L-Val) 4, cyclo-(L-Leu-Hyp) 5, and deferoxamine E 6 were isolated and 
structurally characterized, one of which, DFO-E 6 displayed potent activity against P. falciparum 3D7 
(IC50 = 1.08 µM). 
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